Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with advanced melanoma.
Atara Biotherapeutics (ATRA) stock slips as company faces an FDA clinical hold after rejection of lead candidate Ebvallo.
The FDA filing is supported by data from the phase ... We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that ...
Koh Young Technology, a South Korean mid-sized company specializing in 3D inspection equipment, has seen its stock price ...
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a ...
Investor's Business Daily on MSN5d
Here's How Donald Trump Could Shake Up Health Care — And Biotech StocksBiotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with a lot of ...
Eli Lilly and Company LLY announced that the FDA has granted approval to its drug ... list of today’s Zacks #1 Rank (Strong Buy) stocks here. It's only 1/9,000th the size of NVIDIA which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback